Gilead, Other Biotechs Selling Off On Market Weakness

Market mayhem continues, as Gilead Sciences, Inc. GILD and other biotech companies are selling off on Monday's market weakness.

Gilead

Shares of Gilead were in the red, down -3.52 percent in Monday's early afternoon session.

Gilead Science's weekly performance is hovering around -5.75 percent and the issue has a YTD performance of -3.5 percent.

On last Thursday's trading session, the minimum price at which Gilead Sciences share traded was $101.337 and its peak price of the day was $102.39.

Gilead Sciences has a 52-week range of $86.00 to $123.37. The company has a market cap of $145.51 billion.

More biotechnology stocks also fell on the first trading day of 2016.

And Others

Abbott Laboratories ABT closed on last Thursday's trading session at $44.91.

The company has a market capitalization of 66.99 billion. The 52-week range for Abbott is at $39.00–$51.74.

Valeant Pharmaceuticals Intl Inc VRX shares have experienced a decline of -3.06 as of the time of this writing into Monday's sessions.

The company's 52-week range has been between $69.33 and $263.81. Valeant's weekly performance is down 13.08 percent and YTD performance is down 2.89 percent, while the one-year is down 31.67 percent.

On last Thursday's trading session, the minimum price at which Valeant share traded was $101.04 and its peak price of the day was $103.62.

Traders dumped their shares on Chinese economic slowdown fears and increased turmoil in the Middle East. The Dow Jones industrial average fell 2 percent, following declines in Asia and Europe.